Table 2.
Baseline characteristics of study participants
| All individuals (n = 166) N (%) | Individuals with the T0, T1 and/or T2 AND the T3 questionnaire (n = 117) N (%) | Individuals without the T0, T1 and/or T2 NOR the T3 questionnaire (n = 49) N (%) | P value (n = 117 vs. n = 49) | |
|---|---|---|---|---|
| Age at inclusion, mean (range, SD) | 51 (19–73, 9.7) | 51 (19–73, 9.5) | 51 (30–72, 10.3) | 0.894 |
| Gender, male | 68 (41 %) | 50 (43 %) | 18 (37 %) | 0.473 |
| Genetic background | ||||
| Familial pancreatic cancer (FPC) | 84 (51 %) | 60 (51 %) | 24 (49 %) | |
| CDKN2A (FAMMM syndrome) | 44 (27 %) | 32 (27 %) | 12 (25 %) | |
| BRCA1 (HBOC) | 2 (1 %) | 2 (2 %) | 0 (0 %) | |
| BRCA2 (HBOC) | 25 (15 %) | 17 (15 %) | 8 (16 %) | |
| LKB1 (Peutz–Jeghers syndrome) | 7 (4 %) | 4 (3 %) | 3 (6 %) | |
| TP53 (Li Fraumeni syndrome) | 4 (2 %) | 2 (2 %) | 2 (4 %) | 0.783 |
| Number of PDAC cases in the family, mean (range, SD) | 2 (0–7, 1.2) | 2 (0–7, 1.2) | 2 (0–5, 1.2) | 0.202 |
| Youngest family member affected by PDAC, mean (range, SD) | 51 (21–89, 11.4) | 51 (21–89, 11.4) | 53 (40–80, 11.4) | 0.357 |
| Children | ||||
| Yes | 136 (82 %) | 104 (89 %) | 32 (65 %) | |
| No | 20 (12 %) | 11 (9 %) | 9 (18 %) | |
| No data | 10 (6 %) | 2 (2 %) | 8 (16 %) | 0.042 |
| Marital status | ||||
| Married/co-habiting/LAT relationship | 129 (78 %) | 98 (84 %) | 31 (63 %) | |
| Single/divorced/widowed | 19 (11 %) | 11 (9 %) | 8 (16 %) | |
| No data | 18 (11 %) | 8 (7 %) | 10 (20 %) | 0.095 |
| Level of education | ||||
| Primary school | 3 (2 %) | 3 (3 %) | 0 (0 %) | |
| High school | 39 (24 %) | 27 (23 %) | 12 (25 %) | |
| College/university | 115 (69 %) | 85 (73 %) | 30 (61 %) | |
| No data | 9 (5 %) | 2 (2 %) | 7 (14 %) | 0.486 |
| Smoking behavior | ||||
| Never smoker | 85 (51 %) | 60 (51 %) | 25 (51 %) | |
| Current or past smoker | 67 (40 %) | 50 (43 %) | 17 (35 %) | |
| No data | 14 (8 %) | 7 (6 %) | 7 (14 %) | 0.580 |
| Alcohol consuming | ||||
| Never consumer | 37 (22 %) | 30 (26 %) | 7 (14 %) | |
| Current or past consumer | 114 (69 %) | 81 (69 %) | 33 (67 %) | |
| No data | 15 (9 %) | 6 (5 %) | 9 (18 %) | 0.230 |
| Ever treated for cancer | ||||
| Any type of cancer | 47 (28 %) | 35 (30 %) | 12 (25 %) | |
| Melanoma | 28 (17 %) | 20 (17 %) | 8 (16 %) | |
| Breast cancer | 13 (8 %) | 10 (9 %) | 3 (6 %) | |
| Other | 10 (6 %) | 9 (8 %) | 1 (2 %) | 0.479 |
| Surveillance with | ||||
| EUS & MRI | 159 (96 %) | 112 (96 %) | 47 (96 %) | |
| EUS only | 2 (1 %) | 2 (2 %) | 0 (0 %) | |
| MRI only | 5 (3 %) | 3 (3 %) | 2 (4 %) | 0.576 |
SD standard deviation, FAMMM familial atypical multiple mole melanoma, HBOC hereditary breast and ovarian cancer, PDAC pancreatic ductal adenocarcinoma, LAT living apart together, EUS endoscopic ultrasonography, MRI magnetic resonance imaging
Bold P-values are considered statistically significant